ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV
ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV
Provider: View Press Release Type: Link Title: ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV | GSK Description: Data from the BANNER study show antiviral efficacy, safety, and tolerability of N6LS, supporting its continued study in phase IIb
GSK regulatory submission accepted by Japanese regulator for respiratory syncytial virus older adult vaccine candidate
Provider: View Press Release Type: Link Title: GSK regulatory submission accepted by Japanese regulator for respiratory syncytial virus older adult vaccine candidate | GSK Description: The proposed indication is for adults aged 60 years and above to prevent lower respiratory tract diseases (LRTD) caused by RSV.
New data show Shingrix can provide at least 10 years of protection against shingles in adults aged 50 years and over
Provider: View Press Release Type: Link Title: New data show Shingrix can provide at least 10 years of protection against shingles in adults aged 50 years and over | GSK Description: The ZOSTER-049 extension study shows that Shingrix can provide at least a decade of protection against shingles after initial vaccination
GSK announces expanded collaboration with Tempus in precision medicine to accelerate R&D
Provider: View Press Release Type: Link Title: GSK announces expanded collaboration with Tempus in precision medicine to accelerate R&D | GSK Description: GSK will work together with Tempus to improve clinical trial design, speed up enrolment and identify drug targets.
US FDA approves Menveo in a new single-vial presentation to help prevent disease caused by meningococcal bacteria serogroups A, C, Y, and W
Provider: View Press Release Type: Link Title: US FDA approves Menveo in a new single-vial presentation to help prevent disease caused by meningococcal bacteria serogroups A, C, Y, and W | GSK Description: The Menveo one-vial presentation now comes in a ready to use single vial giving healthcare providers a more convenient option.
GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial
